secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001193125-23-191839
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 3.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics to acquire EryDel for up to 7.25M shares + $485M milestones
-------------------------------------------------------------------------------

- EryDel shareholders get up to 7,250,352 shares (16.7% of combined company) and up to $485M in milestone cash payments, no royalties.
- Quince assumes EryDel's $13M (€10M) EIB loan; payments start H2 2026.
- Preliminary cash, equivalents, and short-term investments of ~$87.6M as of June 30, 2023 to fund operations into 2026.
- CMO Karen Smith to depart effective September 1, 2023; Luca Benatti to join board upon closing.
- Acquisition includes Phase 3 asset EryDex for Ataxia-Telangiectasia under FDA SPA; close expected Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523191839/0001193125-23-191839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523191839/d542769d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-191839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer